Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).

**A**

<table>
<thead>
<tr>
<th>Day 3</th>
<th>20-19 Tan BB06</th>
<th>20-19 Tan Mut06</th>
<th>19-28z</th>
<th>UT</th>
<th>Tumor Control</th>
<th>Naive Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

**Bone Marrow**

19-28z

- CD45 vs CD3
- CD45 vs ProtL
- CD45 vs CD8
- CD45 vs CD20
- CD45 vs CD39
- CD45 vs PD1
- CD45 vs TIM3
- CD45 vs CD45RA

20-19 Tan BB06z

- CD45 vs CD3
- CD45 vs ProtL
- CD45 vs CD8
- CD45 vs CD20
- CD45 vs CD39
- CD45 vs PD1
- CD45 vs TIM3
- CD45 vs CD45RA

20-19 Tan mut06z

- CD45 vs CD3
- CD45 vs ProtL
- CD45 vs CD8
- CD45 vs CD20
- CD45 vs CD39
- CD45 vs PD1
- CD45 vs TIM3
- CD45 vs CD45RA

**C**

**Bone Marrow - ImmunePhenotype**

- Frequency of cells among CAR T
- Frequency of cells among CD4/CD8